Compare ATGL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | FTRE |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.7M | 864.4M |
| IPO Year | 2023 | N/A |
| Metric | ATGL | FTRE |
|---|---|---|
| Price | $23.50 | $15.54 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.36 |
| AVG Volume (30 Days) | 64.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,206,460.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | N/A | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.36 | 1.88 |
| 52 Week Low | $9.01 | $3.97 |
| 52 Week High | $57.32 | $20.86 |
| Indicator | ATGL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 72.01 |
| Support Level | $24.01 | $14.02 |
| Resistance Level | $26.20 | $16.94 |
| Average True Range (ATR) | 2.79 | 1.10 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 43.16 | 77.32 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.